Wyeth

Pfizer Corporation

Osvaldo Dos Santos

Aranapakam Mudumbai Venkatesan

Tarek Suhayl Mansour

Christoph Martin Dehnhardt

Arie Zask

Ariamala Gopalsamy

David James Richard

Kevin Joseph Curran

Efren Guillermo Delos Santos

Jeroen Cunera Verheijen

Joshua Aaron Kaplan

Mengxiao Shi

Zecheng Chen

Semiramis Ayral-Kaloustian

Takao Abe

Atul Agarwal

Yang-I Lin

Fuk-Wah Sum

Tsuyoshi Takasaki

Itsuki Yamamura

Richard Eric Mewshaw

Magda Asselin

Yansong Gu

George Theodore Grosu

Deborah Ann Evrard

Kristin L Meagher

Semiramis Aryl-Kaloustian

Christoph M Dehnhardt

Jeroen C Verheijen

Compounds of formula I  and R, R, and Rare defined herein, and pharmaceutically acceptable salts and esters thereof. These compounds inhibit PI3 kinase and mTOR, and may be used to treat diseases mediated by PI3 kinase and mTOR, such as a variety of cancers. Methods for making and using the compounds of this invention are disclosed. Various compositions containing the compounds of this invention are also disclosed.

Triazine compounds as PI3 kinase and mTOR inhibitors

Triazine compounds as PI3 kinase and MTOR inhibitors

Triazine compounds as P13 kinase and MTOR inhibitors

Compounds of formula I wherein:Ris and R, R, and Rare defined herein, and pharmaceutically acceptable salts and esters thereof. These compounds inhibit PI3 kinase and mTOR, and may be used to treat diseases mediated by PI3 kinase and mTOR, such as a variety of cancers. Methods for making and using the compounds of this invention are disclosed. Various compositions containing the compounds of this invention are also disclosed.

The present invention provides a compound of formula I wherein one of A and B is hydrogen and the other an optionally substituted fused bicyclic heteroaryl group as defined herein; X is O; Ris H, C1-C6 alkyl, C5-C6 cycloalkyl, or CHROCOC1-C6 alkyl; and Ris hydrogen, C1-C6 alkyl, C5-C6 cycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl; or a pharmaceutically acceptable salt thereof; and pharmaceutical compositions and the use thereof for the treatment of bacterial infection or disease in a patient in need thereof.

Bicyclic 6-alkylidene-penems as &#x3b2;-lactamase inhibitors

Benzofuranyl- and benzothienyl-piperzinyl quinoline derivatives and compositions containing such compounds are disclosed. Methods of using benzofuranyl- and benzothienyl-piperzinyl quinoline derivatives and compositions containing such composition in the treatment and/or prevention of serotonin-related disorders, such as depression and anxiety, are also disclosed. In addition, processes for the preparation of benzofuranyl- and benzothienyl-piperzinyl quinoline derivatives are disclosed. Benzofuranyl- and benzothienyl-piperzinyl quinoline derivatives of Formula I are disclosed: 

Benzofuranyl-and benzothienyl-piperazinyl quinolines and methods of their use

3-Piperidin-4-yl-1H-indole and 3-(1,2,3,6-tetrahydro-pyridin-4-yl)-1H-indole derivatives are disclosed. Methods of using the derivatives and compositions containing the derivatives in the prevention and/or treatment of serotonin disorders, such as depression and anxiety, are also disclosed. Additionally, processes for the preparation of 3-piperidin-4-yl-1H-indole and 3-(1,2,3,6-tetrahydro-pyridin-4-yl)-1H-indole derivatives are disclosed.

Piperidinyl indole and tetrohydropyridinyl indole derivatives and method of their use

The present invention provides a compound of formula I, pharmaceutical compositions and the use thereof for the treatment of bacterial infection or disease in a patient in need thereof. wherein one of A and B denotes hydrogen and the other an optionally substituted fused bicyclic heteroaryl group; and X is S.

Growing community of inventors

Astoria, NY, United States of America

Osvaldo Dos Santos